Full Press Release Details
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data
PITTSBURGH , Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTRS ), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025 .
The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models. All accepted scientific abstracts are now available on the PAINWeek website .
Full List of Viatris Presentations at PAINWeek 2025
| Poster Title | Presentation Details |
| Poster #41 Pharmacokinetics study comparing MR-107A-02 (novel fast-acting meloxicam formulation) 15mg tablet with meloxicam (Mobic®) 15mg in healthy adult male subjects. | Live Abstract Presentation Thursday, Sept. 4 4:35 p.m. - 4:45 p.m. PDT |
| Poster #39 Efficacy and safety of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy | Live Abstract Presentation Thursday, Sept. 4 4:50 p.m. - 5:00 p.m. PDT |
| Poster #38 Efficacy and safety of MR-107A-02 (novel meloxicam fast-acting formulation) for the treatment of acute moderate-to-severe pain following herniorrhaphy. | Live Abstract Presentation Thursday, Sept. 4 5:05 p.m. - 5:15 p.m. PDT |
| Poster #40 Opioid sparing effect of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy and herniorrhaphy. | Live Abstract Presentation Thursday, Sept. 4 5:20 p.m. - 5:30 p.m. PDT |
| Poster #76 Efficacy and Safety of a Rapid-Absorption Formulation of Meloxicam in the Treatment of Acute Postoperative Pain Following Bunionectomy and Herniorrhaphy | Poster presentation only |
About Viatris Viatris (Nasdaq: VTRS ) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh , Shanghai and Hyderabad, India . Learn more at viatris.com and investor.viatris.com , and connect with us on LinkedIn , Instagram , YouTube and X .
SOURCE Viatris Inc.